Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.

Arichi, Naoko; Dahiya, Rajvir; Hiraki, Miho; Hiraoka, Takeo; Hirata, Hiroshi; Mitsui, Yozo; Nakamura, Sigenobu; Shiina, Hiroaki; Sumura, Masahiro; Tanaka, Yuichiro; Yasumoto, Hiroaki

Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.

Authors: Naoko Arichi
Rajvir Dahiya
Miho Hiraki
Takeo Hiraoka
Hiroshi Hirata
Yozo Mitsui
Sigenobu Nakamura
Hiroaki Shiina
Masahiro Sumura
Yuichiro Tanaka
Hiroaki Yasumoto
Publication date: 1 January 2015
Publisher: eScholarship, University of California

Abstract

In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cel

Similar works

Full text

Available Versions

Sustaining member

eScholarship - University of California

oai:escholarship.org:ark:/1303...

Last time updated on 25/12/2021